Quarterly ResultMay 8, 2026, 04:38 PM
Integrated BioPharma Q1 Revenue $10.1M, Net Loss $(0.8)M, EPS $(0.03)
AI Summary
Integrated BioPharma reported a significant decline in its financial results for the quarter and nine-month period ended March 31, 2026. Quarterly revenue decreased by 27.3% to $10.1 million, leading to an operating loss of $1.1 million and a net loss of $0.8 million. For the nine-month period, revenue fell by 15.2% to $34.1 million, resulting in a net loss of $1.5 million. Management attributed the revenue decrease primarily to reduced sales from its two largest customers in the Contract Manufacturing Segment.
Key Highlights
- Q1 2026 revenue decreased 27.3% to $10.1 million from $13.9 million in Q1 2025.
- The company reported an operating loss of $1.1 million in Q1 2026, compared to operating income of $0.7 million in Q1 2025.
- Net loss for Q1 2026 was $0.8 million, a decline from net income of $0.6 million in Q1 2025.
- Diluted net loss per share for Q1 2026 was $(0.03), compared to net income per share of $0.02 in Q1 2025.
- Revenue for the nine-month period ended March 31, 2026, decreased 15.2% to $34.1 million from $40.2 million.
- Net loss for the nine-month period was $1.5 million, compared to net income of $1.0 million in the prior year.
- Revenue from the two largest customers in the Contract Manufacturing Segment represented approximately 90% of total revenue for the nine months ended March 31, 2026.